1
|
Argo-Leignel D, Bouju P, Le Saux M, Leissen N, Guégan R, Pointreau Y, Alexandre Y, Bera G. [Clinical research in general hospital centres in France, strengths and weaknesses]. Cancer Radiother 2023; 27:460-463. [PMID: 37573194 DOI: 10.1016/j.canrad.2023.07.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2023] [Revised: 07/07/2023] [Accepted: 07/10/2023] [Indexed: 08/14/2023]
Abstract
Clinical research is an essential activity in cancer care. Both for patients, who can gain access to innovative therapies, and for practitioners, who can maintain their skills and stay at the forefront of new treatment approaches. First developed in university hospitals, clinical research is now established in general hospitals and private health institutions. The number of patient inclusions in clinical trials has doubled over the last ten years, thus reflecting the dynamism of it. Strengths and weaknesses, opportunities and threats concerning clinical research, and more specifically clinical research in general hospitals, are exposed in this article.
Collapse
Affiliation(s)
- D Argo-Leignel
- Groupe hospitalier Bretagne Sud, 5, avenue de Choiseul, 56520 Lorient, France.
| | - P Bouju
- Groupe hospitalier Bretagne Sud, 5, avenue de Choiseul, 56520 Lorient, France
| | - M Le Saux
- Groupe hospitalier Bretagne Sud, 5, avenue de Choiseul, 56520 Lorient, France
| | - N Leissen
- Groupe hospitalier Bretagne Sud, 5, avenue de Choiseul, 56520 Lorient, France
| | - R Guégan
- Groupe hospitalier Bretagne Sud, 5, avenue de Choiseul, 56520 Lorient, France
| | - Y Pointreau
- Institut inter-régional de cancérologie (ILC), centre Jean-Bernard, 64, rue de Degré, 72000 Le Mans, France
| | - Y Alexandre
- Groupe hospitalier Bretagne Sud, 5, avenue de Choiseul, 56520 Lorient, France
| | - G Bera
- Groupe hospitalier Bretagne Sud, 5, avenue de Choiseul, 56520 Lorient, France
| |
Collapse
|
2
|
Fangous MS, Alexandre Y, Hymery N, Gouriou S, Arzur D, Blay GL, Berre RL. Lactobacilli intra-tracheal administration protects from Pseudomonas aeruginosa pulmonary infection in mice - a proof of concept. Benef Microbes 2019; 10:893-900. [PMID: 31965833 DOI: 10.3920/bm2019.0069] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The spreading of antibiotic resistance is a major public health issue, which requires alternative treatments to antibiotics. Lactobacilli have shown abilities to prevent pneumonia in clinical studies when given by oral route, certainly through the gut-lung axis involvement. Rationally, respiratory administration of lactobacilli has been developed and studied in murine model, to prevent from respiratory pathogens. It allows a direct effect of probiotics into the respiratory system. To our knowledge, no study has ever focused on the effect of probiotic intra-respiratory administration to prevent from Pseudomonas aeruginosa (PA) pneumonia, a major respiratory pathogen associated with high morbidity rates. In this study, we evaluated the beneficial activity of three Lactobacillus strains (Lactobacillus fermentum K.C6.3.1E, Lactobacillus zeae Od.76, Lactobacillus paracasei ES.D.88) previously screened by ourselves and known to be particularly efficient in vitro in inhibiting PAO1 virulence factors. Cytotoxic assays in alveolar epithelial cell line A549 were performed, followed by the comparison of two lactobacilli prophylactic protocols (one or two administrations) by intra-tracheal administration in a C57BL/6 murine model of PA pneumonia. A549 cells viability was improved from 23 to 75% when lactobacilli were administered before PAO1 incubation, demonstrating a protective effect (P<0.001). A significant decrease of 2 log of PAO1 was observed 4 h after PAO1 instillation (3×106 cfu/mouse) in both groups receiving lactobacilli (9×106 cfu/mouse) compared to PAO1 group (P<0.05). One single prophylactic administration of lactobacilli significantly decreased the secretion by 50% in bronchoalveolar lavages of interleukin (IL)-6 and tumour necrosis factor-α compared to PAO1. No difference of secretion was observed for the IL-10 secretion, whatever the prophylactic study design. This is the first study highlighting that direct lung administration of Lactobacillus strains protect against PA pneumonia. Next step will be to decipher the mechanisms involved before developing this novel approach for human applications.
Collapse
Affiliation(s)
- M S Fangous
- Laboratoire de Microbiologie, CH Cornouaille, Rue Yves Thepot, 29000 Quimper, France.,Univ Brest, Inserm, EFS, UMR 1078, GGB, 22 avenue Camille Desmoulins, 29200 Brest, France
| | - Y Alexandre
- Université de Brest, EA 3882-Laboratoire Universitaire de Biodiversité et d'Écologie Microbienne (LUBEM), Parvis Blaise Pascal, Technopôle Brest-Iroise, 29280 Plouzané, France
| | - N Hymery
- Université de Brest, EA 3882-Laboratoire Universitaire de Biodiversité et d'Écologie Microbienne (LUBEM), Parvis Blaise Pascal, Technopôle Brest-Iroise, 29280 Plouzané, France
| | - S Gouriou
- Univ Brest, Inserm, EFS, UMR 1078, GGB, 22 avenue Camille Desmoulins, 29200 Brest, France
| | - D Arzur
- Univ Brest, Inserm, EFS, UMR 1078, GGB, 22 avenue Camille Desmoulins, 29200 Brest, France.,Université de Brest, EA 3882-Laboratoire Universitaire de Biodiversité et d'Écologie Microbienne (LUBEM), Parvis Blaise Pascal, Technopôle Brest-Iroise, 29280 Plouzané, France
| | - G Le Blay
- Université de Brest, EA 3882-Laboratoire Universitaire de Biodiversité et d'Écologie Microbienne (LUBEM), Parvis Blaise Pascal, Technopôle Brest-Iroise, 29280 Plouzané, France.,Univ Brest, CNRS, IRD, Ifremer, LEMAR, 29280 Plouzane, France
| | - R Le Berre
- Univ Brest, Inserm, EFS, UMR 1078, GGB, 22 avenue Camille Desmoulins, 29200 Brest, France.,Département de Médecine Interne et Pneumologie, CHRU La Cavale-Blanche, Bd Tanguy Prigent, 29200 Brest, France
| |
Collapse
|
3
|
Miquerol L, Cluzeaud F, Porteu A, Alexandre Y, Vandewalle A, Kahn A. Tissue specificity of L-pyruvate kinase transgenes results from the combinatorial effect of proximal promoter and distal activator regions. Gene Expr 2018; 5:315-30. [PMID: 8836739 PMCID: PMC6138020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The L-type pyruvate kinase (L-PK) gene is regulated by diet and hormones and expressed at high levels in the hepatocytes, enterocytes, and proximal tubular cells of the kidney and at low levels in the endocrine pancreatic cells. Two regulatory regions have been shown to be important in transgenic mice to confer on a reporter gene a similar tissue-specific and diet-responsive expression: a proximal promoter fragment, with binding sites for the tissue-specific hepatocyte nuclear factors 1 and 4, and presence of the glucose-response element (GIRE) and a distal activator corresponding to a liver-specific hypersensitive site at -3000 bp with respect to the cap site. Although the proximal promoter is able to confer by itself tissue-specific expression on a reporter gene, its activity in vivo is strongly stimulated by the distal activator. To determine the possible role of the distal region on diet responsiveness and tissue specificity of the L-PK gene expression, we have created lines of transgenic mice in which the gene for SV40 T antigen (Tag) was directed by composite regulatory sequences consisting of the L-PK promoter and different enhancers: either the SV40 early enhancer (SV) or the H enhancer of the aldolase A gene (H). The induction of the composite H-PK/Tag and SV-PK/Tag transgenes by a carbohydrate-rich diet in the liver was similar to that of the endogenous L-PK gene. This suggests that in fasted mice the L-PK promoter, and especially the GIRE, is able to silence the activating influence of a strong viral enhancer such as the SV40 enhancer. The H-PK/Tag mice expressed the transgene similarly to the endogenous gene, except in the pancreas, where expression was practically undetectable. Consistently, whereas L-PK/Tag mice develop insulinomas, H-PK/Tag mice develop only hepatomas. In contrast, the transgene expression was partly aberrant in SV-PK/Tag mice. In addition to a normal activation of the transgene in the liver, a strong expression was also detected in the kidney medulla, whereas the transgene was practically silent in enterocytes. Finally, the effect of the distal region (-2070 to -3200) on an ubiquitous promoter was tested by ligating the distal L-PK gene fragment in front of a thymidine kinase/CAT transgene. Such a transgene was constantly expressed in the pancreas and, strikingly, in the brain. It appears, therefore, that the L-PK distal activator exhibits, by itself, a certain neuropancreatic specificity required in combination with the proximal promoter for L-PK gene expression in pancreas endocrine cells.
Collapse
Affiliation(s)
- L Miquerol
- Institut Cochin de Génétique Moléculaire, INSERM U 129, Université René Descartes, Paris, France
| | | | | | | | | | | |
Collapse
|
4
|
Alexandre Y, Le Blay G, Boisramé-Gastrin S, Le Gall F, Héry-Arnaud G, Gouriou S, Vallet S, Le Berre R. Probiotics: a new way to fight bacterial pulmonary infections? Med Mal Infect 2013; 44:9-17. [PMID: 23820129 DOI: 10.1016/j.medmal.2013.05.001] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2012] [Revised: 04/03/2013] [Accepted: 05/24/2013] [Indexed: 01/31/2023]
Abstract
Antibiotics, of which Fleming has identified the first representative, penicillin, in 1928, allowed dramatical improvement of the treatment of patients presenting with infectious diseases. However, once an antibiotic is used, resistance may develop more or less rapidly in some bacteria. It is thus necessary to develop therapeutic alternatives, such as the use of probiotics, defined by the World Health Organization (WHO) as "micro-organisms which, administered live and in adequate amounts, confer a benefit to the health of the host". The scope of these micro-organisms is broad, concerning many areas including that of infectious diseases, especially respiratory infections. We describe the rational use of probiotics in respiratory tract infections and detail the results of various clinical studies describing the use of probiotics in the management of respiratory infections such as nosocomial or community acquired pneumonia, or on specific grounds such as cystic fibrosis. The results are sometimes contradictory, but the therapeutic potential of probiotics seems promising. Implementing research to understand their mechanisms of action is critical to conduct therapeutic tests based on a specific rational for the strains to be used, the dose, as well as the chosen mode and rhythm of administration.
Collapse
Affiliation(s)
- Y Alexandre
- Laboratoire universitaire de biodiversité et d'écologie microbienne, EA3882, faculté de médecine, université européenne de Bretagne, CHRU de la Cavale Blanche, boulevard Tanguy-Prigent, 29609 Brest cedex, France
| | - G Le Blay
- Laboratoire de microbiologie des environnements extrêmes, technopole Brest-Iroise, UMR 6197, université européenne de Bretagne, institut universitaire européen de la mer, 29280 Plouzané, France
| | - S Boisramé-Gastrin
- Laboratoire universitaire de biodiversité et d'écologie microbienne, EA3882, faculté de médecine, université européenne de Bretagne, CHRU de la Cavale Blanche, boulevard Tanguy-Prigent, 29609 Brest cedex, France
| | - F Le Gall
- Laboratoire universitaire de biodiversité et d'écologie microbienne, EA3882, faculté de médecine, université européenne de Bretagne, CHRU de la Cavale Blanche, boulevard Tanguy-Prigent, 29609 Brest cedex, France; Unité de bactériologie-virologie, CHRU, 29609 Brest, France
| | - G Héry-Arnaud
- Laboratoire universitaire de biodiversité et d'écologie microbienne, EA3882, faculté de médecine, université européenne de Bretagne, CHRU de la Cavale Blanche, boulevard Tanguy-Prigent, 29609 Brest cedex, France; Unité de bactériologie-virologie, CHRU, 29609 Brest, France
| | - S Gouriou
- Laboratoire universitaire de biodiversité et d'écologie microbienne, EA3882, faculté de médecine, université européenne de Bretagne, CHRU de la Cavale Blanche, boulevard Tanguy-Prigent, 29609 Brest cedex, France
| | - S Vallet
- Laboratoire universitaire de biodiversité et d'écologie microbienne, EA3882, faculté de médecine, université européenne de Bretagne, CHRU de la Cavale Blanche, boulevard Tanguy-Prigent, 29609 Brest cedex, France; Unité de bactériologie-virologie, CHRU, 29609 Brest, France
| | - R Le Berre
- Laboratoire universitaire de biodiversité et d'écologie microbienne, EA3882, faculté de médecine, université européenne de Bretagne, CHRU de la Cavale Blanche, boulevard Tanguy-Prigent, 29609 Brest cedex, France; Département de médecine interne et pneumologie, CHRU, 29609 Brest, France.
| |
Collapse
|
5
|
Affiliation(s)
- G Gragnic
- National Hospital Laboratory, Niamey, Niger
| | | | | | | |
Collapse
|
6
|
Plaisancié H, Alexandre Y, Uzan G, Besmond C, Benarous R, Frain M, Trepat JS, Dreyfus JC, Kahn A. Immunological screening of standard cDNA libraries in pBR322 vectors: detection of human fibrinogen and prothrombin cDNA clones. Anal Biochem 1984; 142:271-6. [PMID: 6397074 DOI: 10.1016/0003-2697(84)90464-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
The in situ immunological detection of antigens encoded by cDNA inserted into the PstI site of pBR322 plasmids was optimized. It was found that sensitivity of the detection was dramatically increased by in situ amplification of the recombinant plasmids on chloramphenicol-containing medium followed by a brief incubation without chloramphenicol during which protein synthesis resumes. In addition, several modifications of the previously described methods which permit total suppression of background and false positives are described. These techniques allowed easy detection of cDNA clones for human B beta- and gamma-fibrinogen and -prothrombin using a human liver double-stranded cDNA recombinant plasmid library in pBR322 vectors.
Collapse
|
7
|
Pichard AL, Daegelen-Proux D, Alexandre Y, Dreyfus JC. Calmodulin ligands. The interaction of muscle phosphorylase kinase with phosphodiesterase. Comparison of calmodulin ligands in muscle extracts from normal and phosphorylase kinase-deficient mice. Biochim Biophys Acta 1981; 657:84-93. [PMID: 6260201 DOI: 10.1016/0005-2744(81)90132-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Interactions between phosphorylase kinase (ATP:phosphorylase-b phosphotransferase, EC 2.7.1.38) and calmodulin were studied with pure preparations of muscle phosphorylase kinase, and with crude extracts from muscles of control (C57 Black) and deficient (ICR/IAn) mice, which lack muscle phosphorylase kinase activity. Calmodulin was determined by its ability to stimulate a calmodulin-dependent phosphodiesterase. The amount of calmodulin bound to phosphorylase kinase in muscle extract was estimated to a maximum of 30% of the total amount of calmodulin. In the muscle of the deficient strain a decrease of 35% in the total amount of calmodulin was observed. This correlates with the absence of the calmodulin fraction specifically bound to phosphorylase kinase. From sucrose gradient studies we demonstrated that in the presence of Ca2+ the amount of calmodulin bound to phosphorylase kinase was enhanced, compared to the control in the presence of EGTA. This observation was made both in crude extracts and in pure phosphorylase kinase preparations. Sucrose gradient also showed that muscle phosphorylase kinase can be dissociated to low molecular species when extracts are made in the presence of Ca+; this dissociation was found to be related to a Ca2+-dependent proteolytic effect.
Collapse
|
8
|
Abstract
ICR/IAn mice present a deficiency in phosphorylase kinase activity; the extent of this deficiency is less in some tissues [Lyon, S.B. Biochem. Genet. 4, 169--185 (1970)] than in skeletal muscle, where enzyme activity is 0.3% of normal [Cohen, P.T. W & Cohen, P. FEBS Lett. 29, 113--115 (1973)]. New-born mice of this strain were also reported (Lyon, 1970) to reveal a small amount of skeletal muscle enzyme activity. The properties of these residual phosphorylase kinases were compared to those of control C57 BL mice, with reference to control muscle and liver enzymes which were shown to be of different molecular species [Daegelen-Proux et al. Biochim. Biophys Acta, 452, 398--405 (1976)]. The properties investigated were the immunological reactivity against an antiserum raised against muscle phosphorylase kinase, the thermal stability and the Ca2+ dependency. The results suggest that the muscle enzyme from the new-born ICR/IAn mice and the heart enzyme from adult deficient mice are different to the muscle enzyme from adult normal mice, but they have properties in common with normal adult liver enzyme. These results lead to the conclusion that there exists in the muscle of I strain a "foetal form" of phosphorylase kinase, the activity of which decreases progressively after birth. Out work also confirmed the observations made by Cohen et al. [Eur. J. Biochem. 66, 347--356 (1976)] which showed that there is no evidence for the existence of a cross-reacting material in the muscle of adult deficient mice.
Collapse
|
9
|
Daegelen-Proux D, Pierres M, Alexandre Y, Dreyfus JC. Molecular heterogeneity of rabbit heart phosphorylase kinase. Biochim Biophys Acta 1976; 452:398-405. [PMID: 12808 DOI: 10.1016/0005-2744(76)90189-3] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Phosphorylase kinase (ATP: phosphorylase-b phosphotransferase, EC 2.7.1.38) from rabbit heart, when submitted to electrophoresis on Pevikon, separates into two discrete peaks A and B. The two peaks have been analyzed using reelectrophoresis, chromatography on DEAE-cellulose, thermal stability, inactivation by EGTA (ethyleneglycol-bis(beta-aminoethyl ether)-N,N'-tetraacetic acid) and reaction with an anti-muscle phosphorylase kinase antiserum. It can be concluded that rabbit heart extracts contain two isozymes of phosphorylase kinase. The more negatively charged isozyme seems to be identical with the muscle enzyme. The other isozyme resembles the liver enzyme but differs from the major fraction of the latter by its charge. It is likely that there exist at least three molecular types of phosphorylase kinase.
Collapse
|
10
|
|
11
|
|
12
|
Dreyfus JC, Alexandre Y. Electrophoretic characterization of acidic and neutral amylo 1-4-glucosidase (acid maltase) in human tissues and evidence for two electrophoretic variants in acid maltase deficiency. Biochem Biophys Res Commun 1972; 48:914-20. [PMID: 4264156 DOI: 10.1016/0006-291x(72)90695-x] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
13
|
Dreyfus JC, Alexandre Y. Immunological studies on glycogen storage diseases type 3 and V. Demonstration of the presence of an immunoreactive protein in one case of muscle phosphorylase deficiency. Biochem Biophys Res Commun 1971; 44:1364-70. [PMID: 5003690 DOI: 10.1016/s0006-291x(71)80236-x] [Citation(s) in RCA: 30] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
14
|
Rosa R, Alexandre Y, Kaplan JC, Dreyfus JC. [Immunological study of erythrocyte glucose-6-phosphate dehydrogenase in deficient mutants]. Clin Chim Acta 1970; 29:209-14. [PMID: 5493178 DOI: 10.1016/0009-8981(70)90038-0] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
15
|
Kaplan JC, Alexandre Y, Dreyfus JC. [Selective deficiency of 1 of the genetic loci of phosphoglucomutase in erythrocytes]. C R Acad Hebd Seances Acad Sci D 1970; 270:1061-3. [PMID: 4986337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|